COMPASS Pathways plc (CMPS) Deep Dive Video
Summary
A de-risked Phase 3 psilocybin leader with massive TRD upside—now bottlenecked by DEA scheduling, reimbursement, and clinic rollout execution.
View CMPS stock page · Read the CMPS research report
Loading the video player…